Amyloid Precursor Protein (APP)
Influence of chlorpyrifos oxon on the development and progression of Alzheimer’s disease in amyloid precursor protein transgenic mice
12
Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer's disease
14
Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease
21
Modulation of β-amyloid precursor protein trafficking and processing by the low density lipoprotein receptor family
13
Pathological correlations between traumatic brain injury and chronic neurodegenerative diseases
10
The autophagy related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid β accumulation in mice
11
Cerebral amyloid angiopathy-related inflammation: a case report presenting with a rare variant in SORL1 gene
6
Identification of the novel activity-driven interaction between synaptotagmin 1 and presenilin 1 links calcium, synapse, and amyloid beta
24
Modeling Alzheimer's disease with non-transgenic rat models
9
Involvement of 5-lipoxygenase activating protein in the amyloidotic phenotype of an Alzheimer’s disease mouse model
10
Original Article DMT1 inhibitor ebselen inhibits iron-induced amyloidogenic APP processing
10
The genetics of Alzheimer's disease
17
Proteomics of protein post translational modifications implicated in neurodegeneration
13
Decreasing the expression of PICALM reduces endocytosis and the activity of β secretase: Implications for Alzheimer's disease
17
The role of APP and BACE1 trafficking in APP processing and amyloid-β generation
8
Alzheimer’s in a dish – induced pluripotent stem cell based disease modeling
13
Neuroinflammation and related neuropathologies in APPSL mice: further value of this in vivomodel of Alzheimer’s disease
13
Neuronally derived extracellular vesicles: an emerging tool for understanding Alzheimer’s disease
9
Early-onset dementias: diagnostic and etiological considerations
22
Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease
5